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Abstract Researchers often attempt to categorize tumors into more homogeneous subtypes to better predict prog-nosis or 
understand pathogenic mechanisms. In clinical research, typically the focus is on prognosis: the tumor subtypes are intended to 
be associated with specific responses to treatment and/or different clinical outcomes. In aetiological research, the focus is on 
identifying distinct pathogenic mechanisms, which may involve different risk factors. We used directed acyclic graphs to present 
a framework for considering potential biases arising in aeti-ological research of tumor subtypes, when there is incomplete 
correspondence between the identified subtypes and the underlying pathogenic mechanisms. We identified two main scenarios: 
(1) weak effect, when the tumor sub-types are identified through combinations of characteristics and some of these 
characteristics are affected by factors that are unrelated with the underlying pathogenic mecha-nisms; and (2) lack of causality, 
when the set of charac-teristics corresponds with a mechanism that is actually not a cause of the tumor of interest. Examples of 
the magnitude of bias that can be introduced in these situations are provided. Although categorization of tumors into 
homogenous subtypes may have important implications for aetiological research and identification of risk factors, the 
characteristics used to classify tumors into subtypes should be as close as possible to the actual pathogenic mechanisms to 
avoid interpretative biases. Whenever our knowledge of these mechanisms is limited, research into risk factors for tumor 
subtypes should first aim to causally link the char-acteristics to the pathogenic mechanisms. 
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Introduction 
 
Clinical and aetiological research often aims to categorize disease entities into more homogeneous subtypes to better 
predict prognosis, or to improve the understanding of pathogenic mechanisms. Typically, a disease is classified into 
subtypes that share specific characteristics. In partic-ular, any characteristic associated with prognosis and/or response to 
treatment may identify subtypes that differ regarding their clinical outcome; however, the same char-acteristics may not 
correspond to specific aetiologic mechanisms, and vice versa.  
Research into the identification of disease subtypes has recently increased due to advances in high-throughput techniques to 
explore molecular patterns, the availability of large biological databases, and the implementation of col-laborative initiatives to 
obtain and analyze large numbers of tissue samples in a standardized fashion. This increased research activity is tightly linked 
with the concept of pre-cision medicine which involves the identification of disease subtypes to better target the treatment, 
estimate prognosis 
  
and/or manage clinical follow-up. This concept is having a particular impact on clinical oncology and cancer research [1], 
but is being adopted also in non-malignant diseases, including, for example, asthma [2], cardiovascular disease [3] and 
diabetes [4].  
A related development is to use disease subtypes in aetiological studies. For example, researchers have identi-fied 
subtypes of breast cancer, based on the expression of ESR1 (estrogen receptor), PGR (progesterone receptor), and ERBB2 
(HER2). Breast cancers with higher expression of ESR1 or PGR can be sub-classified into luminal A or luminal B 
depending on whether the expression of prolif-erative genes (ERBB2 or ki67) is low or high; non-luminal breast cancers 
can be classified as ERBB2? or triple negative, which in turn may be further classified on the basis of expression of basal 
cytokeratins or epidermal growth factor receptor [5]. Additional markers are being evaluated using more in-depth 
molecular profiling [6]. While ESR1, PGR and ERBB2 are usually tested for prognosis and to inform therapeutic choices 
[7], it has been recently proposed to consider breast cancer subtypes for etiological purposes. Epidemiological studies have 
shown that triple negative breast cancer may have specific risk factors [8].  
Traditionally, tumor classification has been primarily based on the anatomical site of origin of the tumor [9]. Then, 
within each tumor site, stratification is typically carried out on the basis of the cell type of origin and, sometimes, other 
specific characteristics. It is now becoming increasingly possible to further subdivide the tumors on the basis of their 
molecular features [10]. Thus the process of identification of tumor subtypes currently goes from the identification of an 
organ-specific tumor (e.g. ‘‘breast cancer’’), to the classification of that tumor into specific subtypes (e.g. ‘‘triple-negative 
breast cancer’’ or even finer subtypes [6, 11]).  
It is debatable whether such tumor subtypes represent subtypes of a single disease, or should be treated as dif-ferent 
diseases. We will approach this issue pragmatically assuming that an organ-specific tumor type has been identified, and 
the issue is whether and how to divide this into subtypes. This approach mimics the current clinical approach to tumor 
heterogeneity: the characterization of tumor subtypes—often based on molecular analyses of the tumor tissue—logically 
follows the diagnosis of the tumor as an organ-specific entity. For example, a patient is first diagnosed with a breast cancer 
and, then, after having the results of immunohistochemistry assays on the tumor tis-sue, that tumor is further subclassified 
on the basis of the receptor status.  
We support the need to reach a clearer definition of tumors in terms of pathogenic mechanisms. However, in this paper 
we argue that aetiological research into tumor 
subtypes may, under some circumstances, be problematic. A better understanding of these limitations is required for appropriate 
planning and interpretation of aetiological studies based on tumor subtypes. It is important to note that prognostic research and 
aetiological research into cancer subtypes have fundamental differences. In prognostic research any characteristic that is strongly 
associated with the clinical outcome of interest (e.g. response to treatment or mortality) may be effectively used to classify the 
patients into risk categories and the cancers into subtypes. There is no need to identify distinct causal pathways related to the 
distinct subtypes and the clinical outcome can be observed and assessed in classical epidemiological studies. Conversely, in 
aetiologic research the focus is on causal pathways and the subtypes should identify distinct (unobserved) pathogenic 
mechanisms. In this paper, we first present a conceptual framework for considering the correspondence between pathogenic 
mechanisms and the identification of the disease subtypes. We then assess two scenarios in which there is not a direct 
correspondence between characteristics and distinct pathogenic mecha-nisms: (1) weak effect, when the tumor subtypes are 
identified through combinations of characteristics and some of these characteristics are affected by factors that are unrelated with 
the underlying pathogenic mechanisms; (2) lack of causality, when the set of characteristics corre-sponds with a mechanism that 
is actually not a cause of the tumor of interest. Finally we provide some suggestions on how to conduct research to establish the 
links between the characteristics and the pathogenic mechanisms. 
 
 
 
Tumor subtypes and pathogenic mechanisms 
 
In the context of aetiological research, tumor subtypes have aetiological value if they identify distinct pathogenic 
mechanisms. In Fig. 1 we use a directed acyclic graph (DAG) to depict the supposed causal relationships between the 
diagnosis of a tumor, the identification of the tumor subtypes, and the associated pathogenic mecha-nisms: E denotes an 
exposure, A denotes a pathogenic mechanism causing an organ-specific tumor T and C is a characteristic that is used alone 
or in combination with other characteristics to define the tumor subtypes S once the tumor T has been diagnosed. Both 
pathogenic mech-anisms (A1, A2) lead to the development of the tumor T. However tumors caused by the two 
mechanisms will show different characteristics (C1 and C2), which are then used to define the disease subtypes S. It is also 
possible that the characteristics used to define the tumor subtypes contribute to the initial diagnosis of the tumor, in which 
case there would be arrows from C1 and C2 to T. How-ever, in the current example, we assume that the 
 
characteristics that are used to define the subtypes are not used to reach the first diagnosis, but are evaluated after the 
diagnosis of the tumor.  
For simplicity, in Fig. 1 and throughout the article we assume that A and C variables are binary. It is thus assumed that 
a tumor can have two subtypes: the first is due to A1 (and identified through C1), the second is due to A2 (and identified 
through C2). If it is biologically possible that A1 and A2 coexist (as, for example, in the case of intratumor heterogeneity), 
then the two subtypes can also coexist. A simple example of the scenario described in Fig. 1 is the sub-classification of 
tumors on the basis of the cell type of origin. For example germ-cell testicular cancer can be divided into seminomas and 
nonseminomas: these are biological and, potentially, clinical different subtypes, and it is not uncommon that a seminoma 
and a nonsemi-noma coexist in the same patient.  
In the model proposed in Fig. 1, the subtypes directly correspond to pathogenic mechanisms. The exposures may act 
specifically on a pathogenic mechanism (E1 or E3) or may be shared by the different pathogenic mechanisms (E2). It 
should be noted that C1 and C2 may be a set of characteristics (rather than single characteristics), which may even 
influence each other, but should still be specific for a single pathogenic mechanism. Furthermore, the dia-gram depicted in 
Fig. 1, as well as the other diagrams that will be used in the manuscript, are simplified models that cannot fully depict the 
complexity of the molecular mechanisms involved in the pathogenic mechanisms lead-ing to a disease. We propose these 
diagrams only as frameworks for discussing possible biases arising in the etiological research of cancer subtypes. To 
illustrate the implications of having such a framework, we can take the example of germ-cell testicular cancer. Studies of 
the aetiologcal heterogeneity of seminomas and nonseminomas typically classify mixed tumors (i.e. those with both 
seminoma and non-seminoma components) together with nonseminomas. This classification is based only on prog-nostic 
considerations, as mixed tumors have a similar prognosis and response to treatment as that of pure non-seminomas. 
However, on the basis of the diagram reported in Fig. 1, we would have to classify mixed tumors together with seminomas 
when we analyze risk factors for semi-nomas and together with nonseminomas when we analyze risk factors for this 
cancer subtype. Alternatively, we could exclude mixed tumors from the study, but aetiologically, there is no reason to 
group mixed tumors only with nonsemimonas. 
 
 
Problems of causal interpretation 
 
It is possible that the assumption of direct correspondence between the characteristics used to define the subtypes and the 
pathogenic mechanism is not valid. This may affect the interpretability of aetiological studies of tumor subtypes. We 
discuss two scenarios, which are shown, respectively, in Fig. 2 (hereafter labeled as ‘‘weak effect’’) and Fig. 3 (hereafter 
labeled as ‘‘lack of causality’’). 
 
Scenario 1: weak effect 
 
In the scenario depicted in Fig. 2a, the set of characteristics C2 is caused by both pathogenic mechanisms A1 and A2, thus 
a subtype is defined by the presence of C1 and C2, while the other subtype has only C2 features. This scenario may apply 
whenever the tumor subtypes are defined by combinations of characteristics (the definition of breast cancer subtypes, for 
example, requires the combination of ESR1 and PGR expression with ERBB2 expression). The situation depicted in Fig. 
2a would lead to correct causal interpretations. However there may be problems of causal interpretation if, as shown in 
Fig. 2b, some of the charac-teristics used to define the tumor subtypes are affected by factors that are unrelated with the 
pathogenic mechanisms. In Fig. 2b, the exposure E4 affects the characteristic C1 without acting on the pathogenic 
mechanism A1. Since C1 is explained also by E4, the pathogenic mechanism A1 is not a necessary and sufficient cause of 
C1 and thus its effect on C1 is weakened (hence the label weak effect).  
The scenario described in Fig. 2b, in which the char-acteristic C1 is caused by both the pathogenic mechanism A1 and 
the exposure E4, may imply that: (1) some individuals have the set of characteristics C1 for mecha-nisms that are unrelated 
with the pathogenic mechanism A1; or that (2) the pathogenic mechanism A1 does not always produce the associated 
characteristics C1. These two mechanisms are not mutually exclusive. Their conse-quence is that individuals who 
experience the pathogenic mechanism A2 can have both C1 and C2 and be spuriously attributed to the pathogenic 
mechanism A1, and, vice versa, individuals who experienced the pathogenic mechanism A1 can have only C2 and be spuriously 
attributed to the pathogenic mechanism A2. If all variables are binary (0 = absent, 1 = present): (1) C1 = 1 does not imply 
necessarily that A1 = 1, as presence of C1 could be due also to E4 = 1, and (2) C1 = 0 does not imply necessarily that A1 = 0, for 
example if there is an interaction between E4 and A1 that produces C1 = 0 when, A1 = 1 and E4 = 1. It follows that presence of 
C1 may occur in absence of A1 and absence of C1 may occur in presence of A1. In a given study, if E4 were known and observed 
one could consider how to treat this variable to decrease the impact of the weak effect problem. Simple adjustment for E4 would 
not be enough. However, regarding the first mechanism dis-cussed above (i.e. C1 is present for other mechanisms than A1) 
analyses could be restricted to the level(s) of E4 (e.g. E4 = 0) in which the probability of C1 = 1 is the lowest. For the second 
mechanism (i.e. interaction between A1 and E4), analyses could be restricted to the value(s) of E4 (e.g. E4 = 0) that does not 
modify the effect of A1 on C1, even if the identification of these E4 strata is not easy and should be based on external 
information. In addition, it could be possible to focus the analyses directly on the C1 and C2 characteristics, instead of using the 
cancer subtypes as the outcome. Associational estimates would be more inter-pretable, provided that each set of characteristics is 
ana-lyzed independently, without adjusting for the other characteristics. 
 
It should be noted that the problems described here relate to the underlying biological mechanisms leading to the tumor 
subtypes, and are therefore different from problems of measurement error and misclassification of the characteristics Cs. 
They occur even if the characteristics Cs are perfectly measured. It should be also noted that in Fig. 2 we implicitly 
assumed that the sets of characteristics C1 and C2 were independent biomarkers of the pathogenic mechanism A1, 
implicitly assuming that C1 could not cause C2. It is however possible that early molecular changes affect later changes, so 
it could be possible to add an arrow from C1 to C2, without altering the concepts discussed in this paragraph. 
 
Scenario 2: lack of causality 
 
A different problem may occur if one of the supposed pathogenic mechanisms leading to the characteristics used to define 
the subtypes is not a cause of the tumor (i.e. the mechanism was wrongly considered as potentially patho-genic for the 
disease of interest). The DAG shown in Fig. 3 depicts such a scenario in which A2 is not a mechanism by which the 
exposures E2 and E3 cause the disease, and thus there is not an arrow from A2 to T. The corresponding characteristic C2 
could still have a prognostic role, but it would not be a marker of a pathogenic mechanism. For example, methylation in 
the promoter of the O6-methyl-guanine methyltransferase (MGMT) gene in glioblastoma affects response to treatment 
with telozolemide (and it is thus relevant clinically), but this molecular alteration might not be a driver in the pathogenesis 
of this cancer type [12]. Under this scenario, any risk factor for A2 (and thus C2) would be associated with both disease 
subtypes defined on the basis of C2 (presence or absence of C2) even if this risk factor does not have any aetiological role 
for the tumor of interest. It should be noted that the lack of an arrow from A2 to T in the DAG shown in Fig. 3 strictly 
implies no causal effect of A2 on T. In practice, lack of causality is difficult to prove and molecular changes that may seem 
to be unrelated with tumor development could eventually be found to have a causal effect. For example, an involvement of 
MGMT methylation in glioblastoma development is possible, even if the main importance of this marker remains clinical 
[13]. 
 
 
 
Numerical examples 
 
The numerical examples presented in this section have an illustrative purpose. It would be thus possible to assess different 
scenarios or use different values for the various parameters involved in Tables 1 and 2. We chose arbitrary values for the 
parameters, but we have been careful to avoid implausible or extreme values.  
In Table 1, we use the scenario of Fig. 2b and consider a tumor caused by two possible pathogenic mechanisms: A1 
which always causes the characteristics C1 and C2, and A2 which always causes only the characteristic C2. We also 
assume that an exposure E3 doubles the risk of A2. We assume that the population risk of A1 is 1 per 1000 and that the 
population risk of A2 is 1 per 1000 when E3 = 0 and 2 per 1000 when E3 = 1. We assume complete case ascer-tainment 
and diagnosis, irrespective of the mechanism involved, and that all variables are measured with no error. We also assume a 
10% risk of developing the characteristic C1 for reasons that are unrelated with the disease of interest (compared to 100% 
of subjects who are affected by A1). Finally, we assume that the two mechanisms A1 and A2 can coexist, even if in this 
particular example this assumption has negligible effects because the risks of A1 and A2 are low.  
Using these assumptions, Table 1 gives an example of the weak effect scenario caused when C1 can occur also in 
individuals without the disease of interest. Although the exposure E3 affects only the pathogenic mechanism A2 (which 
corresponds to tumor subtype 2 - S = 2 -), analyses based on tumor subtypes would suggest that E3 also affects S = 1 
(which corresponds to the unaffected pathogenic mechanism A1).  
In Table 2, we also assume that only 50% of the subjects having the pathogenic mechanism A1 will in fact have the 
characteristic C1. This, in combination with the occurrence of C1 in subjects without the disease, further contributes to the 
interpretative problems due the weak effect scenario: the risk ratio for S = 2 (corresponding to the pathogenic mechanism 
A2) underestimates the effect of E3 on A2 (RR of 1.67 vs. a true RR of 2.00), while the risk ratio for S = 1 further 
overestimates the effect of E3 on A1 (RR of 1.15 vs. a true RR of 1.00). Analyses focused on characteristics C1 and C2 
would reveal no association between E3 and C1 and a relative risk of 1.5 of C2 for E3 (data not shown in Tables).  
Finally, Table 3 gives an example of the lack of causality scenario. There are only two possible subtypes (based on the 
presence or absence of C2) as A2 is not causal for the disease, and thus the pathogenic mechanism A1 (and C1 = 1) is a necessary 
cause. In Table 3 we assume that the population risk of A1 is 1/1000 irrespectively of the level of the exposure E3, while E3 
doubles the risk (from 10 to 20%) of another mechanism A2 unrelated with the tumor of interest. We also assume that A1 always 
causes C1, A2 always causes C2, no case is left undiagnosed and all variables are measured correctly. Since the characteristic C2 
is unrelated with any pathogenic mechanism for the disease, when the analyses are stratified on C2, the overall
 
Table 1 Example of a weak 
effect scenario 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2 Example of a weak 
effect scenario 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3 Example of a lack of 
causality scenario 
 
 
Exposure Pathogenic mechanisma  Subtypeb  
       
  A1 A2  S = 1 (C1 = 1, C2 = 1) S = 2 (C1 = 0, C2 = 1) 
E
3 = 1 0.001 0.002 0.0012 0.0018 
E
3 = 0 0.001 0.001 0.0011 0.0009 
Risk ratioc 1.00 2.00 1.09 2.00  
Probabilities of different combinations of presence of an exposure E3, pathogenic mechanisms A1 and A2, 
characteristics C1 and C2 and subtypes S = 1 (C1 = 1 and C2 = 1) and S = 2 (C1 = 0 and C2 = 1), when the 
characteristic C1 may occur also among subjects without the disease. Relationships among the variables 
are described in Fig. 2b 
a These probabilities are assumed by design (see text for details)  
b These probabilities are obtained on the basis of A1 and A2, assuming that A1 always generates C1 and 
A2 always generates C2 and a 10% risk of developing the characteristic C1 for reasons that are unrelated 
with the disease of interest (see text)  
c  Risk ratios are calculated by dividing the disease probabilities in E3 = 1 for disease probabilities in 
E3 = 0. Other approaches are possible, which, however, would give the same results as we assumed a rare 
disease      
     
Exposure Pathogenic mechanisma  Subtypeb  
       
  A1 A2  S = 1 (C1 = 1, C2 = 1) S = 2 (C1 = 0, C2 = 1) 
      
E3 = 1 0.001 0.002 0.00075 0.00225 
E3 = 0 0.001 0.001 0.00065 0.00135 
Risk ratioc 1.00 2.00 1.15 1.67  
Probabilities of different combinations of presence of an exposure E3, pathogenic mechanisms A1 and A2, 
characteristics C1 and C2 and subtypes S1 (C1 = 1 and C2 = 1) and S2 (C1 = 1 and C2 = 1), when the 
characteristic C1 may occur also among subjects without the disease and the pathogenic mechanism A1 
does not always produce C1. Relationships among the variables are described in Fig. 2b 
a These probabilities are assumed by design (see text for details)  
b These probabilities are obtained on the basis of A1 and A2 and assuming that A1 always causes C2 and 
causes C1 in 50% of the affected subjects, while A2 always causes C2. We also assume a 10% probability 
of C1 in subjects not having A1 (see text)  
c  Risk ratios are calculated by dividing the disease probabilities in E3 = 1 for disease probabilities in 
E
3 = 0. Other approaches are possible, which, however, would give the same results as we assumed a rare 
disease      
      
Exposure Pathogenic mechanisma   Subtypeb  
       
  A1 (causing the disease) A2 (not causing the disease)  non C2-subtype C2-subtype 
      
E3 = 1 0.001 0.2 0.0008 0.0002 
E3 = 0 0.001 0.1 0.0009 0.0001 
Risk ratioc 1.00 2.00 0.89 2.00  
Probabilities of different combinations of presence of an exposure E3, pathogenic mechanisms A1 and A2 
(the latter is not a cause of the disease of interest), characteristics C1 and C2, and C2-subtype (C1 = 1 and 
C2 = 1) and non C2-subtype (C1 = 1 and C2 = 0). The relationships among the variables are described in 
Fig. 3 
a These probabilities are assumed by design (see text for details)  
b These probabilities are obtained on the basis of A1 and A2 and assuming that only A1 causes the disease 
of interest  
c Risk ratios are calculated by 
dividing the disease 
probabilities in E3 = 1 for disease probabilities in E3 = 0. Other approaches are possible, which, however, 
would give the same results as we assumed a rare disease 
 
group of cases is divided into two groups which are in fact homogeneous in terms of aetiology. An exposure E3 affecting 
C2 would thus increase the number of patients labeled as having a ‘‘C2 tumor subtype’’, and thus decrease the number of 
patients with a ‘‘non-C2 like tumor’’. It follows that E3 would be incorrectly considered to be a risk factor for the C2 
tumor subtype and a protective factor for the non-C2 tumor subtype. Analyses focused on the char-acteristics C1 and C2 
would reveal no association between E3 and C1 and a relative risk of 2.0 of C2 for E3 (data not shown in Tables). 
 
 
Discussion 
 
Categorization of tumors into homogenous subtypes can help to identify specific pathogenic mechanisms and thereby 
specific risk factors [14]. There has recently been increasing interest in the definition and detection of tumor subtypes. 
This has been given impetus by recent advances in various omics technologies and the resulting increase in the amount of 
clinically relevant information that is available. Intertumor heterogeneity [15] and molecular pathological epidemiology 
[16–18] are fast developing and influential concepts in cancer research. Molecular patho-logical epidemiology in particular 
has the specific aim of considering molecular pathological signatures to identify more homogenous subtypes in terms of 
etiology and prognosis [19, 20]. This concept has been used also to discuss, in biological terms, apparently paradoxical 
asso-ciations that have been largely debated in recent epidemi-ological literature, namely the situation where a disease risk 
factor is associated with a favorable prognosis among subjects with that disease [21, 22].  
A similar increasing attention to the identification of disease subtypes has been occurring for non-cancer dis-eases. For 
example, already in 1995, an influential paper identified three asthma phenotypes based on combinations of age at onset 
and persistency of wheezing [23]. This classification, as well as subsequent developments includ-ing additional clinical 
characteristics and inflammation markers [24] have been used in a large number of aetio-logical studies on the assumption 
that ‘‘considering these more homogeneous phenotypes in future studies may lead to a better identification of risk factors 
for asthma’’ [25].  
Etiological research of cancer subtypes imposes com-plex methodological challenges, which we have not been 
discussed in this manuscript. First, although epidemiolog-ical research has traditionally focused mainly on multiple 
exposures, studies of subtypes should use adequate designs and statistical methods to deal with multiple outcomes and to 
quantify their heterogeneity [26]. Second, for the sake of simplicity, we have considered scenarios in which the 
characteristics to classify the subtypes are binary but, as recently discussed [20], biomarkers may be ordinal or even 
continuous, thus leading to a wide spectrum of disease subtypes and challenges in the definitions of the cutoffs. 
Furthermore, information from several biomarkers can be combined leading to an even higher level of complexity. Finally, 
measurement of biomarkers, even when binary, is almost inevitably associated with a certain degree of errors and lack of 
reproducibility. This applies for example to consolidated measurements of ESR1, PGR and ERBB2 by 
immunohistochemistry in breast cancer [27] and is undoubtedly a strong caveat when several markers are measured 
through-omics techniques.  
As discussed in this paper, the markers used to sub-classify tumors into tumor subtypes should be as close as possible to 
the actual pathogenic mechanisms. Although this correspondence is crucial to avoid interpretative biases, our knowledge 
of the pathogenic mechanisms is often too limited to assess whether this important criterion has been achieved. The 
classification of breast cancer subtypes, for example, based on the expression of the estrogen and progesterone receptors 
and ERBB2, has been suggested through a cluster analysis and its clinical value has been proven. However, even if studies 
have suggested that known breast cancer risk factors could have different effects depending on breast cancer molecular 
subtypes [8, 28], distinct pathogenic mechanisms for the different subtypes have not yet been demonstrated, while it is 
clear that breast cancer is characterized by a complex molecular heterogeneity [29, 30]. There is thus a tension between the 
identification of molecular features and the possibility to use them in etiological research. A recent commentary on breast 
cancer suggests the existence of only two aetiolog-ical components (which would correlate with the expres-sion of the 
ESR1); it argues that, even if the model may seem too simplistic clinically, it is not too simple for aetiological purposes, 
considering that many molecular alterations may be more linked with tumor progression than with its development [31].  
We suggest that aetiological research into tumor subtypes should first aim to connect the pathogenic mechanisms to the 
relevant characteristics, and then use these characteristics to assess whether the disease sub-types have different risk 
factors. Biological knowledge is a key factor. For example, when the subtypes are iden-tified on the basis of the cell type 
of origin, it can be reasonably assumed, solely on a biological basis, that different cell types are involved in different 
pathogenic mechanisms. They may share risk factors, as, for example, small cell lung carcinoma and lung adenocar-
cinoma are both affected by smoking [32], but the pathogenic mechanisms remain different as they involve different cell 
types.
 
Often, however, biological knowledge is not sufficient to link a characteristic to a pathogenic mechanism and research should 
be conducted with the primary aim of establishing such a link. There are several options. First, characteristics that are evident at 
an early tumor stage are more likely to be causally linked to its aetiology than late characteristics. Tumor cells evolve during the 
tumor lifespan, acquiring new and complex molecular features. If we are however inter-ested in primary prevention and early 
development of the tumor, molecular characteristics acquired at a later stage are less relevant and may easily be affected by 
mechanisms that are not related with the risk factors of interest. Thus, studies that have access to pre-diagnostic tissues are highly 
infor-mative to define tumor subtypes for aetiological studies [33]. Once the subtypes are defined, they can be identified also on 
the diagnostic tissue, but an initial step involving pre-diag-nostic tissue and early molecular characteristics would greatly 
enhance the potential to validly interpret subsequent studies. Second, the risk of interpretative bias may be reduced by defining 
tumor subtypes on the basis of subtype-specific sets of characteristics (i.e. each subtype has different identifying characteristics) 
instead of combinations of characteristics partially shared by different pathogenic mechanisms. This should be taken into 
account, for example, when the tumor subtypes are defined on the basis of an unsupervised cluster analysis, and then a set of 
markers is chosen to characterize each specific cluster. For aetiological research, it is perhaps safer if the characterizing sets of 
markers do not overlap among clusters. Third, in some instances it is possible to directly test whether a characteristic is causally 
involved in tumor development. For example, to understand whether gene-specific methylation is causally involved in tumor 
development, it is possible to study the association between germ-line variants in the DNA methy-lation machinery genes and 
cancer incidence [34]. If an association is found, methylation markers are more likely to be causally involved instead of being 
just epiphenomena. This approach, which is based on the concept of Mendelian randomization, can be carried out for 
characteristics that are known to be affected by germ-line variants.  
In conclusion, categorization of tumors into homoge-nous subtypes may have important implications for aetio-logical 
research and identification of risk factors. However, it is essential that the characteristics used to classify tumors into 
subtypes should be as close as possible to the actual pathogenic mechanisms to avoid interpretative biases. Whenever our 
knowledge of these mechanisms is limited, research into risk factors for tumor subtypes should first aim to causally link 
the characteristics to the pathogenic mechanisms. 
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